View Author
patient treatment hepatitis resistance therapy hepatitis b study response result hepatology baseline adefovir virus level month mutation ef ficacy combination sequencing lamivudine etv monotherapy entecavir sample codon follow-up hbeag hbv dna monotherapy tenofovir hepatitis b virus table liver virological analysis virological response na-na serum combination therapy virologic fication ficacy virologic response range group hbv-dna genotypic baseline hbv dna genotypic resistance breakthrough history week 48 probability gastroenterology 48 weeks cirrhosis department testing inno-lipa na-na ıve patients rescue therapy na-experienced zoulim presence development signi lam adv hbeag status hepatology 2010 vol drug resistance lam-resistance tenofovir disoproxil fumarate infection hbsag lam-resistant mutations hbeag-positive suppression na-na ïve patients hepatology 2012 vol kaplan –meier analysis emtricitabine
7 Most Recent Publications
|
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
(Article)
Zoutendijk, R. Reijnders, J.G.P. Berg, T. Hansen, B.E. Sonneveld, M.J. Wedemeyer, H. Janssen, H.L.A. Zoulim, F. Brown, A. Mutimer, D.J. Deterding, K. Hofmann, W.P. Petersen, J. Fasano, M. Buti, M. |
2013-05-01
|
|
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study
(Article)
Petersen, J. Ratziu, V. Berg, T. Sarrazin, C. Lutgehetmann, M. Buggisch, P. Buti, M. Janssen, H.L.A. Brown, A. Lampertico, P. Schollmeyer, J. Zoulim, F. Wedemeyer, H. Sterneck, M. |
2012-03-01
|
|
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study
(Article)
Si-Ahmed, S.N. Pradat, P. Wedemeyer, H. Janssen, H.L.A. Zoulim, F. Zoutendijk, R. Buti, M. Mallet, V. Cruiziat, C. Deterding, K. Dumortier, J. Bailly, F. Esteban, R. |
2011-10-01
|
|
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
(Article)
Zoutendijk, R. Reijnders, J.G.P. Bömmel, F. van Pradat, P. Oo, Y. Luetgehetmann, M. Berg, T. Hansen, B.E. Wedemeyer, H. Janssen, H.L.A. Brown, A. Zoulim, F. Mutimer, D. Deterding, K. Petersen, J. Hofmann, W.P. Buti, M. Santantonio, T. |
2011-08-01
|
|
Adefovir serum levels do not differ between responders and nonresponders
(Article)
Deterding, K. Naesens, L. Buti, M. Janssen, H.L.A. Kirschner, J. Guerrero, A. Reijnders, J.G.P. Neyts, J. Zoulim, F. Wedemeyer, H. |
2011-07-01
|
|
Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues
(Article)
Reijnders, J.G.P. Deterding, K. Petersen, J. Zoulim, F. Santantonio, T. Buti, M. Bömmel, F. van Hansen, B.E. Wedemeyer, H. Janssen, H.L.A. |
2010-04-01
|
|
Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment
(Article)
Niesters, H.G.M. Zoulim, F. Pichoud, C. Buti, M. Shapiro, F. D'Heuvaert, N. Celis, L. Doutreloigne, J. Sablon, E. |
2010-03-01
|
